Psoriatic Arthritis
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
Clinical Presentation and Subtypes of Psoriasis
Epidemiology and Classification of Psoriasis
Biologic Therapy for Psoriasis
Diagnostic Criteria
Guselkumab brings active psoriatic arthritis into ‘stringent’ control through 2 years
Guselkumab for psoriatic arthritis led to major improvements in joint disease activity, complete skin clearance and other “stringent” endpoints that were maintained through 2 years, according to data published in Clinical Rheumatology.
FDA approves biosimilar Pyzchiva for all approved Stelara indications
The FDA has approved the Stelara biosimilar Pyzchiva for psoriatic arthritis, Crohn’s disease and all other indications approved for the reference medicine, according to a press release from Sandoz.
Juvenile Arthritis Awareness Month encourages children to be #StrongerThanJA
Juvenile arthritis can impact the physical and emotional wellbeing of children in unique ways, manifesting in loneliness and depression, according to the Arthritis Foundation.
Healio Minute Podcast, Rheumatology/Psoriatic Arthritis Edition: Top Headlines - Week of June 24, 2024
In this edition, extensive psoriasis and IBD history predict difficult-to-treat psoriatic arthritis, targeted therapies demonstrate low risk for serious infection and more.
Bimekizumab results in rapid, sustained improvements to PsA patient reported outcomes
Bimekizumab treatment for psoriatic arthritis demonstrated rapid, clinically meaningful improvements to patient reported outcomes that were sustained up to 1 year, according to data published in Rheumatology.